AURORA, Colo., July 17, 2026
Researchers at the University of Colorado Anschutz Medical Campus have reported that the market for compounded GLP-1 weight-loss medications remains highly active even after the U.S. Food and Drug Administration (FDA) ended shortages of branded obesity medicines. Published in JAMA Health Forum, the study found that many medical spas and weight-loss clinics continue to offer compounded versions of semaglutide and tirzepatide, with some products sourced from pharmacies that either lacked sterile compounding licenses or had recent regulatory or disciplinary actions related to sterile compounding practices. While the researchers emphasized that the study did not evaluate the safety, quality, or effectiveness of the compounded medicines themselves, the findings highlight growing concerns surrounding transparency, regulatory oversight, and patient confidence as demand for affordable obesity therapies continues to rise.
Study Reveals Continued Growth of Compounded GLP-1 Market
The research examined the evolving market for compounded GLP-1 receptor agonists after the FDA resumed enforcement against routine compounding following the resolution of national shortages affecting branded obesity medicines. Using a secret shopper methodology, investigators contacted weight-loss clinics and medical spas across Oklahoma and West Virginia to determine product availability, patient monitoring practices, and medication sourcing. Researchers identified 75 clinics continuing to provide compounded GLP-1 therapies despite the return of commercially available products. Many clinics reported offering customized formulations that combined semaglutide or tirzepatide with additional ingredients such as vitamin B12, potentially allowing these products to remain available as individualized compounded prescriptions. The findings suggest that compounded obesity medications continue to represent a significant segment of the weight management market even after supply shortages have ended.
Researchers Highlight Regulatory and Quality Oversight Challenges
A major finding of the study involved the pharmacies supplying compounded GLP-1 medicines to participating clinics. Among 23 compounding pharmacies identified, researchers reported that four lacked licenses required for sterile compounding, while several others had recently received disciplinary actions or FDA warning letters associated with sterile compounding practices. Importantly, investigators stressed that the research did not assess the quality, sterility, safety, or clinical effectiveness of the medications dispensed by these pharmacies. Instead, the study focused on identifying potential regulatory gaps within an expanding marketplace where patients may have limited visibility into how their medications are manufactured. The authors emphasized the importance of increased transparency so patients and healthcare providers can make informed decisions regarding the sourcing of compounded medicines.
Advertisement
Balancing Affordable Obesity Care with Patient Safety
The researchers acknowledged that compounded semaglutide and tirzepatide have played a vital role in expanding access to obesity treatment, particularly for patients unable to afford branded therapies or lacking adequate insurance coverage. However, they cautioned that increasing market complexity presents significant challenges for regulators responsible for overseeing a rapidly growing network of compounding pharmacies. The study calls for regulatory innovation that preserves access to affordable obesity medications while strengthening oversight, improving transparency, and ensuring compliance with sterile compounding standards. Investigators also encourage healthcare professionals and patients to discuss the origin of compounded medications, verify pharmacy credentials, and better understand manufacturing practices before initiating treatment. As demand for GLP-1 therapies continues to expand globally, the findings contribute to ongoing discussions surrounding patient safety, pharmaceutical quality assurance, and regulatory policy within the rapidly evolving obesity treatment landscape.
Source: University of Colorado Anschutz press release
